Skin Cancer & Melanoma

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.

Brachytherapy plaque with vitrectomy and silicone oil was most often given to patients with uveal melanoma tumors sized 2 mm or larger.

Tara A. McCannel, MD, PhD, discusses how brachytherapy plaque with vitrectomy and silicone oil led to a 100% survival rate in patients with uveal melanoma.

Patients with uveal melanoma who have tumors larger than 2 mm are candidates for brachytherapy plaque with vitrectomy and silicone oil.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.

David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.

David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.

Adjuvanted imsapepimut and etimupepimut plus pembrolizumab did not yield a statistically significant PFS improvement as treatment for advanced melanoma.

The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.

Artificial intelligence used in conjunction with clinicians may help standardize and expedite pathology workflows and reduce variability in TIL scoring.

A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.

“It’s a treatment for those patients who don’t have any other effective treatments available,” said Muhammad Umair Mushtaq, MD, on lifileucel in melanoma.

“There is margin to improve on these treatments, but this is a real hope for patients with melanoma,” said Mushtaq on TIL therapies.

The novel cancer vaccine plus pembrolizumab missed statistical significance but generated a clinically meaningful improvement in advanced melanoma.

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.